Amaury E. Fernández-Montalván is leading Boehringer Ingelheim’s global High Throughput Biology (HTB) Innovation Hub since April 2024. Formerly (08.2020-03.2024) he was Director of the HTB group in the Biberach (Germany) R&D site. He previously served for 2+ years as Head of Compound Screening at the SERVIER Research Institute in Croissy-sur-Seine, France. Between 2008 and 2018 he worked as Head of Laboratory in the Assay Development and High Throughput Screening Group of Bayer’s Lead Discovery Unit in Berlin. Before joining Bayer, he trained as postdoctoral research fellow at the Expertise Platform Proteases of the Novartis Institutes of Biomedical Research in Basel (2005-2006), and the Molecular Pharmacology and Compound Screening Department of Merck Serono International S.A. in Geneva (2007-2008). Amaury studied Biochemistry at the University of Havana and obtained his PhD from the Technical University of Munich in 2004. During his career in the pharmaceutical industry, he has been involved as team member and leader of multiple drug discovery programs from early to clinical stages. His main contributions to these projects were the development and execution of biochemical and biophysical screening assays for hit identification campaigns, as well as for compound profiling activities during the hit-to-lead and lead optimization phases. His research has led to the identification of several chemical probes and clinical candidates, as well as to more than 60 patent applications and peer reviewed scientific publications. His current scientific interests include the use of high throughput screening methodologies for the characterization of compound pharmacological- and molecular modes-of-action.